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Abstract. We studied the hypothesis that disturbances in 5-HT6 receptor function in the temporal cortex may contribute to clinical
symptoms of Alzheimer’s disease (AD). 5-HT6 density and 5-HT levels were significantly decreased in a cohort of AD patients
prospectively assessed for cognitive/behavioral symptoms. cAMP formation after stimulation with the selective 5-HT6 receptor
agonist E-6801 was significantly lower (p < 0.01) in AD (170.02 ± 27.53 pmol/mg prot.) compared to controls (823.33 ±
196.67). In addition, the ratio cAMP formation after stimulation with E-6801/5-HT6 receptor density was significantly lower
(p < 0.01) in AD (6.67 ± 0.83) compared to controls (16.67 ± 3.33). Splitting these results by sex, 5-HT6 receptor activation
was significantly lower (p < 0.01) in AD females compared to males (121.67 ± 30.02 vs. 231.67 ± 34.17 pmol/mg prot).
5-HT6 density and 5-HT levels were significantly correlated (p  0.01) in both controls and AD patients, although in AD, this
correlation was lost in females. Psychosis factor was the best predictor of reduced 5-HT levels or adenylate cyclase activity after
E-6801 stimulation, the former result being due to females. It may be suggested that psychotic symptoms may be related to a
dysregulation of 5-HT6 activation by 5-HT in the temporal cortex. These results are discussed in terms of purported influence of
sex and therapeutical approaches to psychosis in AD.
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INTRODUCTION
The serotonergic 5-HT6 receptor was first identified
from rat striatal mRNA [30,33] and the human receptor
was subsequently identified [19]. The human 5-HT6 re-
ceptor is coupled to the stimulation of adenylate cyclase
and have a widespread distribution in the CNS [9,30,
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38]. Immunohistochemical and ultrastructural studies
for 5-HT6 receptors suggest a postsynaptic and main-
ly dendritic localization [10,38], where they can par-
ticipate in 5-HT-mediated control of the discharge of
neurons innervated by serotonergic terminals [11].
The affinity of some antidepressants and atypical an-
tipsychotics for 5-HT6 receptors together with its lo-
calization in the CNS, have prompted interest in the in-
volvement of 5-HT6 receptors in psychiatric disorders.
In addition, a role for 5-HT6 receptors in memory and
learning processes has also been suggested in animal
studies (see review by Woolley et al. [39]). There is a
particular interest in the possible implication of 5-HT6
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receptor dysfunction in Alzheimer’s disease (AD). AD
is a chronic progressive disorder characterised by de-
mentia but often featuring behavioral and psycholog-
ical syndromes referred to as BPSD (behavioral and
psychological symptoms of dementia, [16]). The ex-
tent and nature of BPSD in AD [15] includes: aggres-
sive behavior, overactivity, depression or psychosis. It
is notable that behavioral syndromes in AD may have a
sex-related differential expression [12], i.e., female sex
appears to be a risk factor for delusions [17].
In a previously published work from our group [8],
and in agreement with another work by Lorke et al. [22],
we found significant reductions in 5-HT6 receptor den-
sity in cortical areas of AD patients, and these reduc-
tions were found to be related to some of the behavioral
symptoms of the illness. Continuing with that work,
we studied the hypothesis that disturbances not only
in 5-HT6 receptor expression but also in function may
contribute to the clinical symptoms of AD. In addition,
we checked sex-related effects. We assayed 5-HT6
receptor function in terms of cAMP formation after
5-HT6 receptor stimulation in the temporal cortex of
AD patients with respect to cognitive impairment and
BPSD prospectively assessed in a patient group [15].




Superpure H2O water (SpS, Romil), bovine serum
albumin and polyethyleneimine, 3-isobuthylmethy-
lxanthine, creatine phosphate, creatine phosphoki-
nase, forskolin and Mg-ATP, dithiothreitol were from
Sigma-Aldrich Ltd, Germany. Bio-Rad Protein As-
say Kit were from Bio-Rad, Munich, Germany. GF/B
filters were from Whatman, UK and ecoscint TM
from National Diagnostics, UK. Two cAMP kits were
used: cAMP Biotrack Enzymeimmunoassay System
(RPN225) and [3H] cAMP assay (TRK 432), both
from GE Healthcare, UK. All other chemicals were
purchased from Panreac, USA. [125I]-SB-258585 and
E-6801 were generously provided by GlaxoSmithK-
line, Harlow, UK and Laboratorios Dr. Esteve S.A.,
Barcelona, Spain respectively.
Table 1
Demographic details of controls and patients with AD
Control Alzheimer
Gender (male/female) 11/9 10/12
Age (years) 74.75 ± 6.67 81.06 ± 1.60
range 53–99 64–89
Postmortem delay (h) 39.28 ± 5.40 48.63 ± 6.30
pH 6.28 ± 0.16 6.44 ± 0.10
Values are mean ± S.E.M. pH, standard chemical symbol,
negative log of hydrogen ion concentration; S.E.M, Standard
error of the mean. Values are mean ± S.E.M of the maxi-
mum number of cases available 20 (control) or 22 cases (AD)
in which clinical determinations were performed. Not all
the cases were available for all neurochemical determinations
and the number of cases used for each determination varied
(controls, n = 13–20, AD, n = 15–22). There were no sig-
nificant differences between age, postmortem delay or brain
pH in either control patients or those with dementia (Student’s
t-test, p > 0.05).
Patients and assessment of behavior
A total of 42 postmortem brains from individuals
were included in the study, 20 elderly normal controls
and 22 patients with clinical diagnosis of dementia,
matched for age, gender, postmortem delay and brain
pH (Table 1). Patients were an autopsied subset of
subjects included in a prospective study of behavioral
changes in clinically diagnosed demented patients [15].
At entry to the study, assessment and diagnoses were
made using CAMDEX [31], DMS-III-R criteria [1]
and NINCDS-ADRA criteria [24]. Drug histories were
recorded for all patients; 21 patients were taking tran-
quilizers (neuroleptics, sedative-hypnotics or antide-
pressants). None of the patients with AD received
cholinomimetics. Four behavioral and psychological
syndromes were assessed using the Present Behavioral
Examination (PBE) [14]: depression, overactivity, psy-
chosis and aggressive behaviour [15]. Depression fac-
tor was the sum of 4 components: apparent sadness,
gloomy thoughts, feeling like a failure, and tearfulness.
The overactivity factor consisted of the sum of the high-
est ratings for walking, and trailing and checking. The
psychosis factor was the sum of scores for hallucina-
tions, persecutory ideas and inappropriate anxiety. Ag-
gressive behaviour included physical aggression, ag-
gressive resistance and verbal aggression [18]. Each
component of the syndrome was scored from 0 (absent)
to 2 (severe, the behaviour had occurred on half of the
days or more in the previous 4 weeks). This gives a
maximum score of 6 for the overactivity, psychosis and
aggression factors (and 8 for the depression factor).
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Tissue samples and neuropathology
For all subjects, informed consent for postmortem
examination and for use of tissue for research was ob-
tained. Selection of subjects for the study was based
on tissue availability, not gender, age, or disease severi-
ty. Blocks corresponding to the temporal cortex (Brod-
mann area 20, BA20) were removed and stored at
−80◦C until processed. All 22 patients were found to
meet CERAD criteria [27] for a diagnosis of AD and all
brains were Braak stage V or V1. To partially mitigate
the possible effects of cause of death on neurochemical
determinations, brain pH was measured with deionised
water as an index of acidosis associated with terminal
coma (Table 1). Brain pH is used as an indication of
tissue quality in postmortem research, with pH > 6.1
considered acceptable [2,21].
All subsequent analyses were performed blinded to
clinical information. The present work has been per-
formed in the same sample tissue samples as those pre-
sented in Garcia-Alloza et al. [8]. Not all the cases
were available for all neurochemical determinations.
Serotonin measurements
5-HT and its metabolite 5-HIAA concentrations
were determined by high performance liquid chro-
matography (HPLC) with electrochemical detection
(Waters Spheribor S10 0DS2 4.6 × 150 mm) as pre-
viously reported [23]. Tissue was homogenised in 20
vol of extraction mixture (0.4 M percloric acid; 1 mM
EDTA; 0.1% metabisulphitic acid). Homogenates
were centrifugated 32,500 g for 20 min. The mo-
bile phase consisted of 80:16 (v/v) mixture of buffer
(KH2PO4·2H2O 0.1 M, citric acid 0.1 M, EDTA 1 mM
and octanosulphonic acid 0.74 mM; pH = 3). 5-HT
content was calculated by comparing with a 1 ng stan-
dard. The limit of detection was 1 pg/10 µl. Turnover
was calculated as the ratio 5-HIAA/5-HT.
[125I]-SB-258585 binding to 5-HT6 receptors
[125I]-SB-258585 binding was assayed essentially
as previously reported [13]. Tissue samples were par-
tially thawed and homogenized in 10 vol of ice-cold
50 mM Tris-HCl buffer (pH 7.7) using an Ultra-Turrax
homogenizer. The homogenates were centrifuged at
35,000 g for 20 min and the resulting pellet was re-
homogenized and incubated at 37◦C for 15 min. Fol-
lowing two further centrifugations, membranes were fi-
nally resuspended (approximately 50–80 mg tissue/ml)
and stored at −80◦C until used. All determinations
were carried out in duplicate. [125I]-SB-258585 bind-
ing assays consisted of 320 µl of membrane suspen-
sion (corresponding to approximately to 8 mg tissue),
40 µl of unlabeled SB258585 at concentrations from
1 to 10 nM, and 40 µl of 1 nM [125I]-SB-258585,
to give a final concentration of 0.1 nM. Non specific
binding was determined in the presence of 10 µM SB-
214111. At the end of incubations, tubes were rapidly
filtered under reduced pressure using a cell harvester
on GF/B filters that had been pre-soaked in 0.3% v/v
polyethyleneimine in ice-cold buffer. The amount of
radioactivity bound to filters was measured in a Wal-
lac liquid scintillation counter. Data were subject to
Scatchard analysis to determine the number of binding
sites (Bmax: fmol/mg of protein) and the dissociation
constant (Kd: nM). Protein content was measured us-
ing the assay described by Bradford [3], using bovine
serum albumin as standard.
cAMP levels
Endogenous cAMP levels were assayed using an en-
zyme immunoassay commercial kit (RPN225) follow-
ing manufacturers instructions.
Adenylate cyclase assay
Membrane preparations and enzymatic activity assay
was carried out as the method described by Valdiz a´n
et al. [37], from frozen hippocampal tissue. 25 µL
of membrane suspension (6–12 µg protein/assay) was
preincubated for 15 min on ice in 150 µL of reac-
tion buffer (53 mmol/L N-[2-hydroxyethyl]piperazine-
N’[2-ethane-sulphonic acid] pH 7.4, 0.3 mM EGTA,
5 mM MgCl2, 0.1 mg/mL bovine albumin, 1 mM
dithiothreitol, 0.5 mM 3-isobuthylmethylxanthine, and
the nucleoside triphosphate regeneration system of
5 mM creatine phosphate, 50 units/mL creatine phos-
phokinase), and 20 µL of water (basal activity),
forskolin (1 µM), or the specific 5-HT6 agonist E-6801
(0.01 µM). The reaction was started by addition of
0.5 mM Mg-ATP and incubated at 30◦C for 10 min.
Reactions were stopped by boiling the tubes for 4 min.
Samples were the centrifugated at 13,000 g for 5 min at
4◦C. For cAMP content, 50 µL aliquots of supernatant
were assayed using a commercial protein-binding as-
say kit (TRK432) combining the high specificity and
affinity for cAMP of a high purified and stabilized bind-
ing protein with an improved charcoal separation step.
Membrane protein concentrations were determined us-
ing the Bio-Rad Protein Assay Kit.
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Statistical analysis
Data were analysed using SPSS for Windows, release
11.0. Normality was checked by Shapiro-Wilks’s test
(p > 0.05). Student’s t-test was used in initial compar-
isons between control patients and patients with AD.
The effects of demographic factors (age, postmortem
delay and brain pH) on neurochemical variables, inter-
correlation between neurochemical variables or rela-
tionships between severity of dementia (MMSE score
at last interview before death), and neurochemical mea-
sures were determined by Pearson’s or Spearman’s cor-
relation coefficients, according to the normality of vari-
ables. Multiple regression analysis using “stepwise”
method was used to investigate possible relationships
between neurochemical variables and psychiatric as-
sessment. As individual patients may show more than
one clinical symptom (depression, overactivity, psy-
chosis and aggressive behaviour) multiple-regression
indicates the strongest correlate between one of these
clinical symptoms and the neurochemical variable [26].
All data was re-analyzed separately by sex.
RESULTS
There were no significant correlations between age,
postmortem delay or brain pH and any of the neuro-
chemical variables studied in either control patients or
those with dementia (p > 0.05). Demographic details
of subjects are shown in Table 1.
Mean last scores before death (± s.e.m.) for cogni-
tive status, measured as MMSE, was 5 ± 1.2. Mean
last scores before death (± s.e.m.) for BPSD assessed
by PBE in AD patients were as follows: depression
factor 3 ± 0.3 (range varies between 1-6); overactivity
3 ± 0.4 (range varies between 1–6); psychosis 2 ± 0.3
(range varies between 0–6); aggressive behavior 5 ±
0.4 (range varies between 1–6).
Serotonergic markers in Alzheimer’s disease
Significant decreases in 5-HT levels (up to 46%, p <
0.01), 5-HIAA (up to 49%, p < 0.001) and the density
of 5-HT6 receptor binding (up to 54%, p < 0.01) were
found in the temporal cortex of AD patients (n = 20,
controls and 22, AD). 5-HT turnover (5-HIAA/5-HT)
was similar in AD and control patients (5.03± 0.41 vs.
5.55 ± 0.50).
As shown in Fig. 1, 5-HT6 receptor density and 5-
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Fig. 1. Significant correlations (Pearson’s correlation coefficient)
between 5-HT levels and 5-HT6 receptor density in the temporal
cortex in control (n = 20, diamond symbols), total AD patients (n =
22, square symbols) and male AD patients (n = 12, circle symbols).
cortex of both controls (n = 20, r = 0.619*,p = 0.004)
and AD patients (n = 22, r = 0.534*, p = 0.010).
In AD, this correlation was lost in females, whereas a
strong correlation was observed male patients (n = 10;
r = 0.836*; p = 0.005).
5-HT6 receptor function
Total cAMP levels were significantly reduced (p <
0.01) in the temporal cortex of AD samples (n = 16)
compared to controls (n = 16) (1.69± 0.09 vs. 2.15±
0.25 fmol/mg tissue).
Basal adenylate cyclase activity was similar in AD
(n = 15) and control patients (n = 13) (157.51± 32.52
vs. 160.01 ± 42.51 pmol/mg prot). Stimulation of
adenylate cyclase activity by the non-specific activator
forskolin, 1 µM, yielded similar results in AD (613.33
± 157.51 pmol/mg prot, n = 15) and controls (679.17
± 186.67 pmol/mg prot, n = 13).
As shown in Fig. 2, cAMP formation after stimula-
tion with the 5-HT6 receptor agonist E-6801, 0.01 µM,
was significantly lower (p < 0.01) in AD samples
(n = 13, controls, n = 15, AD) (170.02 ± 27.53 vs.
823.33±196.67 pmol/mg prot, 4.72 vs. 414.37% of in-
crease). In addition, the ratio cAMP formation after
stimulation with E-6801/5-HT6 receptor density was
significantly lower (p < 0.01) in AD (n = 15) com-
pared to controls (n = 13) (6.67 ± 0.83 vs. 16.67 ±
3.33). In AD, splitting some of these results by sex,
both cAMP induced by E-6801 and the ratio cAMP for-
mation after stimulation with E-6801/5-HT6 receptor
density were significantly lower (p < 0.01) in females
(n = 8) compared to males (n = 7) (121.67 ± 30.02
vs. 231.67 ± 34.17 pmol/mg prot and 5.67 ± 0.91 vs.
8.80 ± 1.33 respectively).
cAMP formation after stimulation with E-6801 was
significantly correlated to 5-HT levels in controls (n =
13, r = −0.615*, p = 0.015), not in AD (n = 15, r =
−0.238, p > 0.05)









































Fig. 2. A) cAMP formation and B) ratio cAMP formation after stimulation with E-6801/5-HT6 receptor density, in the temporal cortex of control
and AD patients (n = 13–15). E-6801: 5-HT6 receptor agonist-induced cAMP formation. ∗∗Statistically significant, control vs. AD, p < 0.01,
Student t-test.
Relationship with clinical symptoms of Alzheimer’s
disease
No significant correlations were found between 5-
HT6 receptor density or adenylate cyclase activity af-
ter E-6801 stimulation and cognitive status (MMSE or
MMSE decline). Correlation coefficients were as fol-
lows: 5-HT6 receptor density and MMSE (n = 21,
r = 0.120, p > 0.05) and MMSE decline (n = 21,
r = 0.145, p > 0.05); adenylate cyclase activity after
E-6801 stimulation and MMSE (n = 15, r = −0.072,
p > 0.05) and MMSE decline (n = 15, r = −0.178,
p > 0.05).
Regarding behavioral symptoms, the best predictor
for reductions in adenylate cyclase activity after E-6801
stimulation was the psychotic behavior score (n = 13,
adjusted r2 =−0.513*; p < 0.037). Stepwise multiple
regression indicated that psychosis factor was the best
predictor for reduced 5-HT levels (n = 20; adjusted
r2 = 0.267; p = 0.028). A more detailed analysis
revealed that this result was largely due to females (fe-
males, n = 11; adjusted r2 = 0.450; p = 0.024; males
n = 9; adjusted r2 = 0.029; p > 0.05).
DISCUSSION
In animal studies, previous works have exam-
ined the purported localization of 5-HT6 receptors in
serotonergic/non-serotonergic neurons [9,23]. Exten-
sive degeneration of serotonergic neurons in the ante-
rior raphe area following microinfusion with 5, 7-DHT
produced no changes in 5-HT6 mRNA levels in the nu-
cleus accumbens, striatum or hippocampus of the rat,
suggesting that 5-HT6 receptors are not located in sero-
tonergic neurons, and that these receptors do not func-
tion as autoreceptors in these regions [9]. Supporting
this idea, an injection of a 5-HT6 receptor antagonist
was ineffective in modulating 5-HT release within the
striatum [5]. However, to our knowledge, little work
has been done in humans. An important finding of the
current study is the correlation between 5-HT levels
and 5-HT6 receptors in AD males, but not in AD female
patients. Even though these results could be explained
simply in terms of neurodegenerative processes, it is
also possible to speculate on the involvement of 5-HT6
receptors in sensing the concentration of 5-HT in the
extracellular milieu, as previously suggested in electron
microscopy studies [4]. Therefore, it is possible that,
even in situations of extensive neurodegeneration, such
as AD, the expression of 5-HT6 receptors is regulated
by its own neurotransmitter, 5-HT. In this sense, sero-
tonin terminal regions (cerebral cortex and striatum,
substantia nigra, facial nucleus, trigeminal nucleus) are
also enriched in 5-HT6 receptor-like immunoreactivi-
ty [10]. However, the possibility of 5-HT6 receptors
mediating 5-HT release cannot be completely excluded,
since concomitant administration of SB-271046 with
amphetamine induced an elevation in striatal 5-HT lev-
els, suggesting that 5-HT6 receptors could somehow be
modulating serotonergic neurotransmission [5]. Future
studies, using double labelling techniques in human tis-
sue, may give a clearer answer on the location/function
of 5-HT6 receptors.
The 5-HT6 receptor has become an increasingly
promising target for improving cognition, at least in
animal studies, in which different 5-HT6 receptor an-
tagonists have shown their ability to improve learning
and memory in several cognitive paradigms and to re-
verse scopolamine-induced learning deficits [25,28,29,
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39]. It has been suggested that the purported 5-HT 6 re-
ceptor’s influence on memory is mediated at least par-
tially by increased cholinergic neurotransmission [23].
However, in our hands, neither 5-HT6 receptor expres-
sion [8] nor function (present data) correlated to the
cognitive status, measured as MMSE.
The high affinity of atypical antipsychotics such as
clozapine for 5-HT6 receptors and their possible mod-
ulation of 5-HT6 expression in the hippocampus [7]
have led to the investigation of 5-HT6 receptors in the
therapeutic properties of these drugs. In support of this
hypothesis, a 5-HT6 receptor polymorphism (267C/T)
has been reported to affect clozapine response [40] and
is a risk factor for schizophrenia [36]. However, it
has also been described that an altered 5-HT6 receptor
density does not contribute to schizophrenia [6]. In
agreement with this idea, previously reported data from
our group [8] showed that 5-HT6 receptor expression
was not associated with psychotic symptoms in AD.
A possible alteration in 5-HT6 receptor function was
addressed next. Even though reductions in total lev-
els of cAMP were found, probably representing neu-
rodegeneration, it is notable that cAMP is generated
by many different receptors, and the fraction generat-
ed by 5-HT6 receptors is probably very small with re-
spect to the total receptor stimulated levels of cAMP.
Therefore, cAMP formation related to 5-HT6 receptor
activation was measured as the amount of cAMP for-
mation after 5-HT6 receptor activation by the selective
agonist E-6801 [31]. It could be argued that the de-
creases in E-6801 induced cAMP formation found in
AD may be due to the decreases in 5-HT6 receptor den-
sity. However, the amount of cAMP found after each
5-HT6 receptor activation (ratio cAMP formation after
E-6801/5-HT6 receptor binding) was also significantly
lower in AD, suggesting that in AD, the dysregulation
of the serotonergic system affects not only the num-
ber of 5-HT6 receptors expressed but also the signal
transduction system. Even more, these parameters of
5-HT6 receptor function seem to be especially affect-
ed in females. Decreases in cAMP formation after E-
6801 stimulation were the best predictor for psychotic
symptoms. In addition, when 5-HT levels were not
correlated to 5-HT6 receptor density (females), cAMP
induced by E-6801 was significantly lower, and the best
predictor for 5-HT levels in temporal cortex was the
psychotic factor. In light of our findings, it is possible
to argue that psychotic symptoms could be related to a
dysregulation of the activation of 5-HT6 receptors by
5-HT. There are previous studies describing that sex is
related to psychosis in AD [12], and female gender ap-
pears to be a risk factor for delusions [17]. Supporting
the present findings of an involvement of 5-HT6 recep-
tor function in psychotic symptoms of AD in females,
it has been reported that male patients respond better
to risperidone [20] and clozapine [35] than female pa-
tients.
Atypical antipsychotics are becoming the main ther-
apeutic group used in schizophrenia treatment. Howev-
er, there is little consensus as to what constitutes atyp-
icality in antipsychotic medication [34]. The affinity
for 5-HT6 receptors showed by some atypical antipsy-
chotics, such us clozapine, and the high levels of 5-
HT6receptors in areas where antipsychotics are thought
to exert their effect, has led to the suggestion that 5-
HT6 receptors contribute to the therapeutic properties
of these drugs. From the present results it might be
suggested that, in the temporal cortex, psychotic symp-
toms in AD may be related to a dysregulation of the ac-
tivation of 5-HT6 receptors by 5-HT, at least in females.
This relationship does not appear to relate to cognitive
deficits in AD, but may relate to dementia-associated
psychosis, or even more, perhaps to psychosis more
generally. Future research will help us to fully under-
stand the exact nature of the relationship between 5-
HT and 5-HT6 receptors and their relationship with the
underlying mechanism for psychosis in AD.
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